Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies

NCT06325748 is registered in ClinicalTrials.gov with Senti Biosciences as lead sponsor.

NCT NCT06325748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06325748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies
Lead sponsor
Senti Biosciences
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 22, 2024
Completion date
August 31, 2040
Enrollment
21 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

aml/mds, cd33 expressing hematological malignancies, flt3 expressing hematological malignancies